TP53 and glioblastoma: While TP53 oncogenic variants have earned notoriety for their adverse prognostic implications in various cancer types, including breast cancer, esophageal carcinoma, and leukemia, their precise role in dictating outcomes for glioblastoma patients remains an enigma (10, 11).